Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30.3M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
19.7M
-
Shares change
-
+1.71M
-
Total reported value, excl. options
-
$948M
-
Value change
-
+$89.7M
-
Number of buys
-
71
-
Number of sells
-
-42
-
Price
-
$48.02
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2022
138 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2022.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.7M shares
of 30.3M outstanding shares and own 65.18% of the company stock.
Largest 10 shareholders include FMR LLC (3.68M shares), ORBIMED ADVISORS LLC (1.68M shares), BlackRock Inc. (1.64M shares), ALKEON CAPITAL MANAGEMENT LLC (1.39M shares), VANGUARD GROUP INC (1.05M shares), STATE STREET CORP (968K shares), Nantahala Capital Management, LLC (792K shares), Candriam S.C.A. (626K shares), PRICE T ROWE ASSOCIATES INC /MD/ (621K shares), and First Light Asset Management, LLC (592K shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.